Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07248163

Universal CAR-T Cell Therapy for NHL

Led by Bioray Laboratories · Updated on 2025-11-25

6

Participants Needed

1

Research Sites

156 weeks

Total Duration

On this page

Sponsors

B

Bioray Laboratories

Lead Sponsor

S

Shanghai Tongji Hospital, Tongji University School of Medicine

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a single-center, single-arm, open-label clinical study, and the sample size is set to 3-6 subjects.

CONDITIONS

Official Title

Universal CAR-T Cell Therapy for NHL

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Willing to participate and sign informed consent
  • Age 18 years or older
  • Estimated survival time of at least 3 months
  • At least one measurable lesion
  • CD19 expression positive
  • ECOG performance score of 0-1
  • Hematology, coagulation, and biochemistry results meet study requirements
  • Left ventricular ejection fraction (LVEF) of 55% or higher
  • No severe lung disorders
Not Eligible

You will not qualify if you...

  • Pregnant or breastfeeding women
  • Previous allogeneic cell therapies, including stem cell transplant
  • Prior anti-CD19 targeted therapy
  • Previous CAR-T cell or genetically modified T cell treatments
  • History of Richter's transformation of chronic lymphocytic leukemia
  • Uncontrolled infections requiring systemic treatment
  • Positive for hepatitis B, hepatitis C, HIV, or syphilis with active infection
  • Severe mental health disorders or CNS diseases
  • Active autoimmune disorders needing immunotherapy within past 2 years
  • Primary immunodeficiency
  • History of other cancers
  • Severe cardiovascular diseases
  • Any condition increasing risk or interfering with study as judged by investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shanghi Tongji Hospital (Tongji Hospital of Tongji University)

Shanghai, China, 620000

Actively Recruiting

Loading map...

Research Team

P

Ping Li, phD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Universal CAR-T Cell Therapy for NHL | DecenTrialz